Under a new partnership with Megalabs, Medterra CBD products will now be sold in Mexico, Argentina and Brazil, Medterra announced in a news release.
With the populations in these countries showcasing an increased interest in high-quality CBD products, Medterra will help Megalabs expand throughout Latin America, the release said.
Cannabidiol (CBD) products are “commonly used to address anxiety, and for patients who suffer through the misery of insomnia,” according to Harvard Health Publishing.
The agreement gives Megalabs exclusive rights to sell Medterra products in Brazil, Mexico and Argentina.
"Over this last year, we have been working with the Megalabs team to plan this entrance into the Latin America markets," Medterra CEO Jay Hartenbach said in the release. "Our success to date has always been centered around strategic partners and we believe Megalabs is exactly the team we need to be successful in these countries. To bring high-quality CBD to those that need it has been our singular goal since Medterra's inception and this marks a significant step in reaching that goal."
Megalabs CEO Gianclaudio Broggi said both companies will benefit from this partnership.
“With this agreement, Megalabs is strengthening its wide-ranging portfolio and entering a new therapeutic field with CBD in areas like pain and anxiety," Broggi said. "This cooperation unites Megalabs and Medterra in the pursuit of innovation, the quest for growth and the possibility of delivering to patients alternative treatment options.”
Alerts Sign-up